• Publications
  • Influence
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
The first trans-ancestry association study of IBD is reported, with genome-wide or Immunochip genotype data from an extended cohort of 86,640 European individuals and immunochip data from 9,846 individuals of East Asian, Indian or Iranian descent, implicate 38 loci in IBD risk for the first time.
Efficacy and safety of CT‐P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
The biosimilar of infliximab, CT‐P13, has recently been shown to be equivalent to infliximab in both efficacy and safety in the treatment of rheumatologic diseases. However, no data are available
The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus
It is shown that metformin use in CRC patients with diabetes is associated with lower risk of CRC‐specific and overall mortality and after adjustment for clinically relevant factors, met formin use showed lowerrisk of overall mortality.
Superior Mesenteric Artery Syndrome: Where Do We Stand Today?
This is the largest case series to document the clinical features and changes in diagnostic modalities, medical and surgical managements, and their outcomes in SMAS patients.
Gene Expression–Based Recurrence Prediction of Hepatitis B Virus–Related Human Hepatocellular Carcinoma
A gene expression signature is identified that effectively predicted early recurrence of HCC independent of microarray platforms and cohorts, and provided novel biological insights into the mechanisms of tumor recurrence.
Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea
CT-P13 was well tolerated and efficacious in patients with IBD and positive outcomes for response/remission were reported regardless of whether patients had received prior infliximab or not.
Guggulsterone inhibits angiogenesis by blocking STAT3 and VEGF expression in colon cancer cells.
It is suggested that guggulsterone not only induces apoptosis, but also inhibits angiogenesis and metastasis in colon cancer cells by blocking STAT3 and VEGF expression, suggesting its therapeutic potential in the treatment of colorectal cancer.
Nonsteroidal anti‐inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer
NSAIDs could selectively reduce the colon CSCs and suppress 5‐FU‐induced increase of C SCs via inhibiting PTGS2 and NOTCH/HES1, and activating PPARG and decreased CBFRE and increased PPRE transcriptional activity and their relative protein expressions.